Belantamab mafodotin for active lupus
Part of Immune system & allergy, Skin clinical trials.
This study tests whether adding a drug called belantamab mafodotin to the usual lupus treatments can help reduce disease activity and lower a specific antibody in the blood (anti-dsDNA). It is for people with moderate to severe lupus who have not had good results with previous medications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 60 years old.
- You need a confirmed diagnosis of systemic lupus erythematosus (SLE) according to standard criteria.
- Your lupus must be active, with a moderate to severe level of disease activity as measured by a standard score.
- You must have a positive anti-dsDNA antibody test (a blood test that measures lupus-related antibodies).
- You must have tried at least one standard lupus treatment that either did not work or caused side effects.
- Your kidneys must be working reasonably well (no need for dialysis).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental cell therapy that targets a specific type of immune cell (B cell) to calm the overactive immune response in lupus, which may help reduce symptoms. It is for people with active lupus that has not responded well to other treatments.
This trial tests belimumab to see if it can improve lupus (SLE) disease activity in people who were diagnosed within the last two years. You may be eligible if your lupus is currently mild to moderate and your background lupus medicines are stable.
This trial compares two medications, telitacicept and belimumab, to see which is safer and more effective for treating lupus. It might help you if standard treatments haven't worked well for you.
This study tests a new investigational drug called SCTB35 for people with active systemic lupus erythematosus (SLE or lupus). It aims to see if the drug is safe and effective in controlling lupus activity when added to your current stable lupus medications.
This study looks at how well belimumab works in people with systemic lupus erythematosus (SLE), a condition where the immune system attacks the body. It aims to see if the treatment helps, regardless of how well it worked in the past.
This study tests belantamab mafodotin, a medicine designed to target amyloid-producing abnormal cells, in people with relapsed or refractory AL (light-chain) amyloidosis. It’s aimed at improving blood and organ-related signs of the disease after earlier treatments have stopped working.
Hear when a new SLE - Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.